Real-World Patients’ Diagnosis-to-Treatment Journey with Nontuberculous Mycobacterial Pulmonary Disease: A Cross-Sectional Survey
Introduction The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC)....
Gespeichert in:
| Veröffentlicht in: | Infectious diseases and therapy Jg. 13; H. 8; S. 1907 - 1920 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Cheshire
Springer Healthcare
01.08.2024
Springer Springer Nature B.V Adis, Springer Healthcare |
| Schlagworte: | |
| ISSN: | 2193-8229, 2193-6382 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Introduction
The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by
Mycobacterium avium
complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5.
Methods
We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5.
Results
Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient’s symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426],
p
< 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were “entirely satisfied” with their patients’ treatment outcomes.
Conclusions
Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies.
Plain Language Summary
Mycobacteria are microorganisms that cause a disease in the lungs known as nontuberculous mycobacterial pulmonary disease (NTM-PD). The number of people with NTM-PD is increasing globally. This study was a survey of doctors who treated people with NTM-PD in Japan and Europe and aimed to understand geographical similarities and differences in the management, treatment, and health of people with NTM-PD. In the survey, treatment for NTM-PD was found to be often delayed or not started. In Japan, this was most commonly because the individual’s symptoms were not thought to be serious enough and in Europe because of delays in laboratory testing needed to decide which antibiotic treatment should be used. The most common treatment goal in both Japan and Europe was improvement in the individual’s symptoms. Clinical guidelines recommend continuing treatment for at least 12 months after the person with NTM-PD has tested negative for mycobacteria. There were similarities and differences in the healthcare settings, clinical presentation, and management of people with NTM-PD between Japan and Europe. It is important to ensure uniform implementation of the treatment guidelines for NTM-PD in each clinical setting so that people with NTM-PD experience better health outcomes. |
|---|---|
| AbstractList | The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5.INTRODUCTIONThe incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5.We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5.METHODSWe analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5.Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient's symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were "entirely satisfied" with their patients' treatment outcomes.RESULTSOverall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient's symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were "entirely satisfied" with their patients' treatment outcomes.Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies.CONCLUSIONSSimilarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies. Introduction The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5. Methods We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5. Results Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient's symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were "entirely satisfied" with their patients' treatment outcomes. Conclusions Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies. IntroductionThe incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5.MethodsWe analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5.ResultsOverall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient’s symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were “entirely satisfied” with their patients’ treatment outcomes.ConclusionsSimilarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies.Plain Language SummaryMycobacteria are microorganisms that cause a disease in the lungs known as nontuberculous mycobacterial pulmonary disease (NTM-PD). The number of people with NTM-PD is increasing globally. This study was a survey of doctors who treated people with NTM-PD in Japan and Europe and aimed to understand geographical similarities and differences in the management, treatment, and health of people with NTM-PD. In the survey, treatment for NTM-PD was found to be often delayed or not started. In Japan, this was most commonly because the individual’s symptoms were not thought to be serious enough and in Europe because of delays in laboratory testing needed to decide which antibiotic treatment should be used. The most common treatment goal in both Japan and Europe was improvement in the individual’s symptoms. Clinical guidelines recommend continuing treatment for at least 12 months after the person with NTM-PD has tested negative for mycobacteria. There were similarities and differences in the healthcare settings, clinical presentation, and management of people with NTM-PD between Japan and Europe. It is important to ensure uniform implementation of the treatment guidelines for NTM-PD in each clinical setting so that people with NTM-PD experience better health outcomes. Introduction The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5. Methods We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5. Results Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient’s symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were “entirely satisfied” with their patients’ treatment outcomes. Conclusions Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies. Plain Language Summary Mycobacteria are microorganisms that cause a disease in the lungs known as nontuberculous mycobacterial pulmonary disease (NTM-PD). The number of people with NTM-PD is increasing globally. This study was a survey of doctors who treated people with NTM-PD in Japan and Europe and aimed to understand geographical similarities and differences in the management, treatment, and health of people with NTM-PD. In the survey, treatment for NTM-PD was found to be often delayed or not started. In Japan, this was most commonly because the individual’s symptoms were not thought to be serious enough and in Europe because of delays in laboratory testing needed to decide which antibiotic treatment should be used. The most common treatment goal in both Japan and Europe was improvement in the individual’s symptoms. Clinical guidelines recommend continuing treatment for at least 12 months after the person with NTM-PD has tested negative for mycobacteria. There were similarities and differences in the healthcare settings, clinical presentation, and management of people with NTM-PD between Japan and Europe. It is important to ensure uniform implementation of the treatment guidelines for NTM-PD in each clinical setting so that people with NTM-PD experience better health outcomes. Abstract Introduction The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5. Methods We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5. Results Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient’s symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were “entirely satisfied” with their patients’ treatment outcomes. Conclusions Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies. Mycobacteria are microorganisms that cause a disease in the lungs known as nontuberculous mycobacterial pulmonary disease (NTM-PD). The number of people with NTM-PD is increasing globally. This study was a survey of doctors who treated people with NTM-PD in Japan and Europe and aimed to understand geographical similarities and differences in the management, treatment, and health of people with NTM-PD. In the survey, treatment for NTM-PD was found to be often delayed or not started. In Japan, this was most commonly because the individual’s symptoms were not thought to be serious enough and in Europe because of delays in laboratory testing needed to decide which antibiotic treatment should be used. The most common treatment goal in both Japan and Europe was improvement in the individual’s symptoms. Clinical guidelines recommend continuing treatment for at least 12 months after the person with NTM-PD has tested negative for mycobacteria. There were similarities and differences in the healthcare settings, clinical presentation, and management of people with NTM-PD between Japan and Europe. It is important to ensure uniform implementation of the treatment guidelines for NTM-PD in each clinical setting so that people with NTM-PD experience better health outcomes. The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5. We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5. Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient's symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were "entirely satisfied" with their patients' treatment outcomes. Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies. The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and five countries within Europe (Eur5; France, Germany, Italy, Spain, and the UK) are caused by Mycobacterium avium complex (MAC). This study describes the clinical decision-making process associated with the management of patients with NTM-PD in Japan and the Eur5. We analyzed data from a survey conducted between July 2013 and October 2013 among physicians treating patients with NTM-PD in clinical practice to compare the healthcare settings, clinical presentation, and patient management in Japan and the Eur5. Overall, 619 physicians (Japan, 173; Eur5, 446) participated in the survey. Most patients in Japan (85%) and the Eur5 (79%) were diagnosed with MAC-PD. Patients were managed generally in hospital-based outpatient clinics (117/173, 68%) in Japan and research/teaching hospitals affiliated with medical schools (140/446, 31%) in the Eur5. The most common reason for delaying treatment was the patient's symptoms not being considered serious enough for treatment (55/128, 43%) in Japan and awaiting results of antimicrobial susceptibility testing (44/151, 29%) in the Eur5. Culture negativity was less commonly achieved after treatment in patients in Japan versus those in the Eur5 (31% [73/238] vs. 70% [300/426], p < 0.0001). In treatment phases that were either completed or discontinued, the primary goal was symptomatic improvement, followed by achieving culture conversion, in both Japan and the Eur5. Overall, 19% (16/85) of physicians in Japan and 43% (220/511) in the Eur5 were "entirely satisfied" with their patients' treatment outcomes. Similarities and differences exist in the healthcare settings, clinical presentation, and management of patients with NTM-PD in Japan and the Eur5. Insufficient consideration of culture status by physicians, delayed treatment initiation, and symptom-based cessation emphasize the need for educational efforts on the guideline-based strategies. |
| Audience | Academic |
| Author | Wagner, Dirk Griffith, David E. van Ingen, Jakko Morimoto, Kozo Gallagher, Jack R. |
| Author_xml | – sequence: 1 givenname: Kozo surname: Morimoto fullname: Morimoto, Kozo email: morimotok@fukujuji.org organization: Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association – sequence: 2 givenname: Jack R. surname: Gallagher fullname: Gallagher, Jack R. organization: Clarity Pharma Research LLC – sequence: 3 givenname: Dirk surname: Wagner fullname: Wagner, Dirk organization: Division of Infectious Diseases, Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg – sequence: 4 givenname: David E. surname: Griffith fullname: Griffith, David E. organization: Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health – sequence: 5 givenname: Jakko surname: van Ingen fullname: van Ingen, Jakko organization: Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38985411$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1DAUhiNUREvpC7BAkdiwcfElF5sNGg23ogIVLWJpOY4zdeXExXaKpisknoLX40k46QwtU6EqUhLZ__8dn-P_YbY1-MFk2WOC9wnG9fNYYEIJwrRAmGBSost72Q4lgqGKcbq1_ueUiu1sL8YzjEHPCyLqB9k244KXBSE72c_PRjn01QfX5kcqWTOk-PvHr_yVVYvBRxtR8ugkGJV62Mrf-zEMZpl_t-k0_-iHNDYm6NH5MeYflto3SicTrHL50eh6P6iwBFQ0KpoX-SyfBx8jOjY6Wdhz-fEYLszyUXa_Uy6avfV3N_vy5vXJ_B06_PT2YD47RLrCPKHWYE1xLVpRMcxYgyluMWtqTesam4IXBeEVKzGHNyk50U3TkaJsOKsb0nWK7WYHK27r1Zk8D7aH40mvrLxa8GEhVUhWOyNpqwTFldK6KgtOay4MbTmpmg4DuODAerlinY9Nb1oNwwnKbUA3dwZ7Khf-QhJCq4rRCgjP1oTgv40mJtnbqI1zajAwTslwXQtRMlGD9Okt6dl0DzArUEF7lRC0vFEtFHRgh85DYT1B5YxDTigTbCq7_x8VPK3prYaMdRbWNwxP_u30usW_GQIBXQn0dLvBdNcSguWUVbnKqgSkvMqqvAQTv2XSNqkpFnAc6-62spU1Qp1hYcLNNO5w_QGsQv2w |
| CitedBy_id | crossref_primary_10_1186_s12879_024_10020_z crossref_primary_10_1016_j_resinv_2025_08_007 crossref_primary_10_1177_23743735251367077 crossref_primary_10_1513_AnnalsATS_202408_904FR crossref_primary_10_2147_IDR_S543622 |
| Cites_doi | 10.1164/ajrccm/137.6.1280 10.1016/j.ccm.2023.08.012 10.1186/s12890-019-0901-z 10.1164/rccm.200604-571ST 10.1016/j.chest.2023.06.014 10.1183/23120541.00574-2020 10.1016/j.rmed.2024.107627 10.1183/13993003.01855-2016 10.1016/j.rmed.2020.106164 10.1513/AnnalsATS.201304-085OC 10.1016/j.chest.2021.08.046 10.21037/jtd.2020.01.39 10.1378/chest.13-2538 10.1016/j.chest.2019.12.016 10.1016/j.rmed.2019.10.002 10.1186/s12890-020-1165-3 10.1183/13993003.00535-2020 10.1016/j.ijid.2022.10.013 10.1513/AnnalsATS.201806-366OC 10.1183/23120541.00097-2019 10.3389/fimmu.2020.00303 10.1016/j.chest.2023.06.015 10.11400/kekkaku1923.48.5_203 10.1183/13993003.00170-2018 10.1080/17476348.2021.1887734 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 Springer Copyright Springer Nature B.V. Aug 2024 The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 Springer – notice: Copyright Springer Nature B.V. Aug 2024 – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7X7 7XB 8AO 8C1 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1007/s40121-024-01015-z |
| DatabaseName | Springer Nature Link CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2193-6382 |
| EndPage | 1920 |
| ExternalDocumentID | oai_doaj_org_article_2da9206acc65482789e2d816bf081c48 PMC11266326 A802423936 38985411 10_1007_s40121_024_01015_z |
| Genre | Journal Article |
| GeographicLocations | United Kingdom France United States Japan Germany Spain Europe |
| GeographicLocations_xml | – name: United Kingdom – name: Spain – name: Germany – name: United States – name: France – name: Japan – name: Europe |
| GroupedDBID | -A0 0R~ 2VQ 3V. 4.4 53G 5VS 7RV 7X7 8AO 8C1 8FI 8FJ AAKKN ABDBF ABEEZ ABUWG ACACY ACGFS ACUHS ACULB ADBBV ADINQ ADRAZ AEUYN AFGXO AFKRA AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAPOH BAWUL BCNDV BENPR BKEYQ BPHCQ BVXVI C24 C6C CCPQU DIK EBS EJD ESX FYUFA GROUPED_DOAJ HMCUK HYE HZ~ IAO IHR ITC KQ8 M48 M~E NAPCQ O9- OK1 PIMPY PQQKQ PROAC RPM RSV SISQX SMD SOJ UKHRP ~JE AAYXX AFFHD CITATION PHGZM PHGZT PJZUB PPXIY NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c608t-de0c2079d963033b020d03b7c2770e484418635088631581cbbf145b837b1ffa3 |
| IEDL.DBID | C24 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001270032100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2193-8229 |
| IngestDate | Fri Oct 03 12:50:53 EDT 2025 Tue Nov 04 02:06:00 EST 2025 Wed Oct 01 14:12:39 EDT 2025 Fri Nov 07 23:39:40 EST 2025 Sat Nov 29 13:59:45 EST 2025 Sat Nov 29 10:38:58 EST 2025 Fri Apr 25 03:25:44 EDT 2025 Sat Nov 29 02:39:48 EST 2025 Tue Nov 18 22:24:01 EST 2025 Fri Feb 21 02:40:11 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | Survey Treatment Europe Japan Real-world Nontuberculous mycobacterial pulmonary disease Culture conversion |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c608t-de0c2079d963033b020d03b7c2770e484418635088631581cbbf145b837b1ffa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1007/s40121-024-01015-z |
| PMID | 38985411 |
| PQID | 3083769925 |
| PQPubID | 2034749 |
| PageCount | 14 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2da9206acc65482789e2d816bf081c48 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11266326 proquest_miscellaneous_3077995397 proquest_journals_3083769925 gale_infotracmisc_A802423936 gale_infotracacademiconefile_A802423936 pubmed_primary_38985411 crossref_primary_10_1007_s40121_024_01015_z crossref_citationtrail_10_1007_s40121_024_01015_z springer_journals_10_1007_s40121_024_01015_z |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-01 |
| PublicationDateYYYYMMDD | 2024-08-01 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cheshire |
| PublicationPlace_xml | – name: Cheshire – name: New Zealand – name: Philadelphia |
| PublicationTitle | Infectious diseases and therapy |
| PublicationTitleAbbrev | Infect Dis Ther |
| PublicationTitleAlternate | Infect Dis Ther |
| PublicationYear | 2024 |
| Publisher | Springer Healthcare Springer Springer Nature B.V Adis, Springer Healthcare |
| Publisher_xml | – name: Springer Healthcare – name: Springer – name: Springer Nature B.V – name: Adis, Springer Healthcare |
| References | Loebinger, Quint, van der Laan (CR7) 2023; 164 Izumi, Morimoto, Uchimura, Ato, Hasegawa, Mitarai (CR18) 2020 Danho, Schildkraut, Zweijpfenning (CR20) 2022; 161 Dahl, Mølhave, Fløe (CR2) 2022; 125 Tsukamura, Shimoide, Kita (CR13) 1973; 48 Furuuchi, Morimoto, Kurashima (CR22) 2020; 157 Park, Kang, Han (CR6) 2019; 19 Schildkraut, Gallagher, Morimoto (CR9) 2020; 173 Morimoto, Izumi, Ato, Hasegawa, Mitarai (CR11) 2019; 158 Izumi, Morimoto, Hasegawa (CR5) 2019; 16 CR12 Park, Chong, Kim (CR23) 2020; 12 Tsukamura, Kita, Shimoide, Arakawa, Kuze (CR14) 1988; 137 Adjemian, Prevots, Gallagher, Heap, Gupta, Griffith (CR1) 2014; 11 Ratnatunga, Lutzky, Kupz (CR3) 2020 Daley, Iaccarino, Lange (CR19) 2020; 56 Griffith, Aksamit, Brown-Elliott (CR10) 2007; 175 Ali (CR17) 2021; 15 Kim, Park, Choi, Kim, Kwak, Yim (CR25) 2023; 164 Fujiwara, Watanabe, Uesugi (CR21) 2024; 226 van Ingen, Wagner, Gallagher (CR8) 2017; 49 van Ingen, Aksamit, Andrejak (CR4) 2018; 51 Wallace, Brown-Elliott, McNulty (CR26) 2014; 146 Kwak, Kim, Choi, Lee, Lee, Yim (CR24) 2020; 20 Prevots, Marshall, Wagner, Morimoto (CR15) 2023; 44 Faverio, De Giacomi, Bodini (CR16) 2021 DR Prevots (1015_CR15) 2023; 44 K Furuuchi (1015_CR22) 2020; 157 SC Park (1015_CR6) 2019; 19 K Izumi (1015_CR5) 2019; 16 P Faverio (1015_CR16) 2021 N Kwak (1015_CR24) 2020; 20 CL Daley (1015_CR19) 2020; 56 JY Kim (1015_CR25) 2023; 164 YE Park (1015_CR23) 2020; 12 K Morimoto (1015_CR11) 2019; 158 J Ali (1015_CR17) 2021; 15 J van Ingen (1015_CR4) 2018; 51 K Fujiwara (1015_CR21) 2024; 226 JA Schildkraut (1015_CR9) 2020; 173 R Danho (1015_CR20) 2022; 161 1015_CR12 M Tsukamura (1015_CR14) 1988; 137 M Tsukamura (1015_CR13) 1973; 48 RJ Wallace Jr (1015_CR26) 2014; 146 VN Dahl (1015_CR2) 2022; 125 DE Griffith (1015_CR10) 2007; 175 J van Ingen (1015_CR8) 2017; 49 MR Loebinger (1015_CR7) 2023; 164 J Adjemian (1015_CR1) 2014; 11 K Izumi (1015_CR18) 2020 CN Ratnatunga (1015_CR3) 2020 |
| References_xml | – volume: 137 start-page: 1280 year: 1988 end-page: 1284 ident: CR14 article-title: Studies on the epidemiology of nontuberculous mycobacteriosis in Japan publication-title: Am Rev Respir Dis doi: 10.1164/ajrccm/137.6.1280 – volume: 44 start-page: 675 year: 2023 end-page: 721 ident: CR15 article-title: Global epidemiology of nontuberculous mycobacterial pulmonary disease: a review publication-title: Clin Chest Med doi: 10.1016/j.ccm.2023.08.012 – volume: 19 start-page: 140 year: 2019 ident: CR6 article-title: Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: a nationwide population-based study publication-title: BMC Pulm Med doi: 10.1186/s12890-019-0901-z – volume: 175 start-page: 367 year: 2007 end-page: 416 ident: CR10 article-title: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200604-571ST – volume: 164 start-page: 1115 year: 2023 end-page: 1124 ident: CR7 article-title: Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis publication-title: Chest doi: 10.1016/j.chest.2023.06.014 – year: 2021 ident: CR16 article-title: Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics publication-title: ERJ Open Res. doi: 10.1183/23120541.00574-2020 – ident: CR12 – volume: 226 start-page: 107627 year: 2024 ident: CR21 article-title: Beyond symptoms: radiologic identification of asymptomatic complex pulmonary infections publication-title: Respirat Med. doi: 10.1016/j.rmed.2024.107627 – volume: 49 start-page: 1601855 year: 2017 ident: CR8 article-title: Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases publication-title: Eur Respir J doi: 10.1183/13993003.01855-2016 – volume: 173 year: 2020 ident: CR9 article-title: Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimation publication-title: Respir Med doi: 10.1016/j.rmed.2020.106164 – volume: 11 start-page: 9 year: 2014 end-page: 16 ident: CR1 article-title: Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201304-085OC – volume: 161 start-page: 370 year: 2022 end-page: 372 ident: CR20 article-title: Mycobacterium growth indicator tube time-to-positivity can serve as an early biomarker of treatment response in mycobacterium avium complex pulmonary disease publication-title: Chest doi: 10.1016/j.chest.2021.08.046 – volume: 12 start-page: 338 year: 2020 end-page: 348 ident: CR23 article-title: Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic complex lung disease publication-title: J Thorac Dis doi: 10.21037/jtd.2020.01.39 – volume: 146 start-page: 276 year: 2014 end-page: 282 ident: CR26 article-title: Macrolide/azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease publication-title: Chest doi: 10.1378/chest.13-2538 – volume: 157 start-page: 1442 year: 2020 end-page: 1445 ident: CR22 article-title: Treatment duration and disease recurrence following the successful treatment of patients with complex lung disease publication-title: Chest doi: 10.1016/j.chest.2019.12.016 – volume: 158 start-page: 67 year: 2019 end-page: 69 ident: CR11 article-title: Actual practice of standard treatment for pulmonary nontuberculous mycobacteriosis in Japan publication-title: Respir Med doi: 10.1016/j.rmed.2019.10.002 – volume: 20 start-page: 126 year: 2020 ident: CR24 article-title: Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study publication-title: BMC Pulm Med doi: 10.1186/s12890-020-1165-3 – volume: 56 start-page: 2000535 year: 2020 ident: CR19 article-title: Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline publication-title: Eur Respir J doi: 10.1183/13993003.00535-2020 – volume: 125 start-page: 120 year: 2022 end-page: 131 ident: CR2 article-title: Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review publication-title: Inte J Inf Dis doi: 10.1016/j.ijid.2022.10.013 – volume: 16 start-page: 341 year: 2019 end-page: 347 ident: CR5 article-title: Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201806-366OC – year: 2020 ident: CR18 article-title: Population-based survey of antimycobacterial drug use among patients with non-tuberculosis mycobacterial pulmonary disease publication-title: ERJ Open Res. doi: 10.1183/23120541.00097-2019 – year: 2020 ident: CR3 article-title: The rise of non-tuberculosis mycobacterial lung disease publication-title: Front Immunol doi: 10.3389/fimmu.2020.00303 – volume: 164 start-page: 1108 year: 2023 end-page: 1114 ident: CR25 article-title: Microbiological cure at treatment completion is associated with longer survival in patients with complex pulmonary disease publication-title: Chest doi: 10.1016/j.chest.2023.06.015 – volume: 48 start-page: 203 year: 1973 end-page: 211 ident: CR13 article-title: A study on the frequency of “atypical” mycobacteria and of “typical” mycobacterioses in Japanese National Chest Hospitals publication-title: Kekkaku(Tuberculosis) doi: 10.11400/kekkaku1923.48.5_203 – volume: 51 start-page: 1800170 year: 2018 ident: CR4 article-title: Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement publication-title: Eur Respir J doi: 10.1183/13993003.00170-2018 – volume: 15 start-page: 663 year: 2021 end-page: 673 ident: CR17 article-title: A multidisciplinary approach to the management of nontuberculous mycobacterial lung disease: a clinical perspective publication-title: Expert Rev Respir Med doi: 10.1080/17476348.2021.1887734 – ident: 1015_CR12 – volume: 157 start-page: 1442 year: 2020 ident: 1015_CR22 publication-title: Chest doi: 10.1016/j.chest.2019.12.016 – volume: 48 start-page: 203 year: 1973 ident: 1015_CR13 publication-title: Kekkaku(Tuberculosis) doi: 10.11400/kekkaku1923.48.5_203 – volume: 19 start-page: 140 year: 2019 ident: 1015_CR6 publication-title: BMC Pulm Med doi: 10.1186/s12890-019-0901-z – volume: 56 start-page: 2000535 year: 2020 ident: 1015_CR19 publication-title: Eur Respir J doi: 10.1183/13993003.00535-2020 – volume: 16 start-page: 341 year: 2019 ident: 1015_CR5 publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201806-366OC – volume: 158 start-page: 67 year: 2019 ident: 1015_CR11 publication-title: Respir Med doi: 10.1016/j.rmed.2019.10.002 – volume: 125 start-page: 120 year: 2022 ident: 1015_CR2 publication-title: Inte J Inf Dis doi: 10.1016/j.ijid.2022.10.013 – volume: 12 start-page: 338 year: 2020 ident: 1015_CR23 publication-title: J Thorac Dis doi: 10.21037/jtd.2020.01.39 – volume: 226 start-page: 107627 year: 2024 ident: 1015_CR21 publication-title: Respirat Med. doi: 10.1016/j.rmed.2024.107627 – volume: 20 start-page: 126 year: 2020 ident: 1015_CR24 publication-title: BMC Pulm Med doi: 10.1186/s12890-020-1165-3 – volume: 44 start-page: 675 year: 2023 ident: 1015_CR15 publication-title: Clin Chest Med doi: 10.1016/j.ccm.2023.08.012 – volume: 146 start-page: 276 year: 2014 ident: 1015_CR26 publication-title: Chest doi: 10.1378/chest.13-2538 – volume: 11 start-page: 9 year: 2014 ident: 1015_CR1 publication-title: Ann Am Thorac Soc doi: 10.1513/AnnalsATS.201304-085OC – volume: 175 start-page: 367 year: 2007 ident: 1015_CR10 publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.200604-571ST – volume: 15 start-page: 663 year: 2021 ident: 1015_CR17 publication-title: Expert Rev Respir Med doi: 10.1080/17476348.2021.1887734 – volume: 161 start-page: 370 year: 2022 ident: 1015_CR20 publication-title: Chest doi: 10.1016/j.chest.2021.08.046 – year: 2020 ident: 1015_CR3 publication-title: Front Immunol doi: 10.3389/fimmu.2020.00303 – volume: 137 start-page: 1280 year: 1988 ident: 1015_CR14 publication-title: Am Rev Respir Dis doi: 10.1164/ajrccm/137.6.1280 – volume: 164 start-page: 1108 year: 2023 ident: 1015_CR25 publication-title: Chest doi: 10.1016/j.chest.2023.06.015 – volume: 164 start-page: 1115 year: 2023 ident: 1015_CR7 publication-title: Chest doi: 10.1016/j.chest.2023.06.014 – volume: 173 year: 2020 ident: 1015_CR9 publication-title: Respir Med doi: 10.1016/j.rmed.2020.106164 – volume: 51 start-page: 1800170 year: 2018 ident: 1015_CR4 publication-title: Eur Respir J doi: 10.1183/13993003.00170-2018 – volume: 49 start-page: 1601855 year: 2017 ident: 1015_CR8 publication-title: Eur Respir J doi: 10.1183/13993003.01855-2016 – year: 2021 ident: 1015_CR16 publication-title: ERJ Open Res. doi: 10.1183/23120541.00574-2020 – year: 2020 ident: 1015_CR18 publication-title: ERJ Open Res. doi: 10.1183/23120541.00097-2019 |
| SSID | ssj0001284197 |
| Score | 2.313166 |
| Snippet | Introduction
The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases... The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases in Japan and... Introduction The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases... IntroductionThe incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of NTM-PD cases... Mycobacteria are microorganisms that cause a disease in the lungs known as nontuberculous mycobacterial pulmonary disease (NTM-PD). The number of people with... Abstract Introduction The incidence and prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) are increasing globally. Approximately 80% of... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1907 |
| SubjectTerms | Antibiotics Care and treatment Culture conversion Decision-making Europe France Germany Health care Hospitals Infectious Diseases Internal Medicine Japan Laboratory tests Lung diseases Medical colleges Medical diagnosis Medical personnel Medicine Medicine & Public Health Microorganisms Nontuberculous mycobacterial pulmonary disease Original Research Patients Pharmaceutical industry Physicians Polls & surveys Practice Real-world Schools Spain Survey United Kingdom United States |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQhRAXxD-BgoyExAEs7NhJHG5LoeLS1YoWqTcrdhyx0mq3SjaVtiekPkVfjydhxsmGTRFw4bp2srZnxvM5nvmGkFeA0X2hlGOAheCAoj3ug16wIvaV5aoSjheh2EQ2nerT03y2U-oLY8I6euBu4d7FZZHHPC2cwwrnmLfp41KL1FbgzJwKab6AenYOU93XFa1EqKwCFikZspr3GTMhb04hkxkD98SQYi1hFyOvFMj7f9-id3zU9fjJa5eowTcd3iV3elBJJ91k7pEbfnmf3Drqr80fkMsvAAdZiJuhs45Itfnx_Yp-7OLs5g1br9jJNuScdgRHG4rfaOl0BV7J-tq1i1Xb0KONgx0gMDzDP87aBahxUW_gVeGi5z2d0AOcIjsOMV44rOO2Pvebh-Tr4aeTg8-sr77AXMr1mpWeu5hneQkmyqW0gCtLLm3m4izjXmnAURrQCuxSqRQJyMLaSqjEwonXiqoq5COyt1wt_RNCAZQkNnc2TUquvMhBNtpWGXfWJ5VMqoiI7eob11OTY4WMhRlIlYPEDEjMBImZi4i8GZ4564g5_tr7Awp16Imk2uEHUDXTq5r5l6pF5DWqhEHTh-G5os9ggEkiiZaZaAQ8MpdpRPZHPcFk3bh5q1Sm3zIaIwEMZ2mex0lEXg7N-CSGwS09yBj6ZEjgBxgyIo87HRymBMhTJ0qIiOiRdo7mPG5Zzr8FQnFMI0sBx0fk7VaRf43rz4v69H8s6jNyOw6GiDGV-2RvXbf-Obnpztfzpn4RrPonyvdMpA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgi1AvvB-BgoKExAGs2omTOFzQtrTi0tWqLVJvVuw4sNJq0ya7lbYnJH4Ff49fwozj3TZF9MJ17WQ9noe_2ONvCHkLGN0WQhgKWAg-UKTFOGg5LSJbaSYqbljhik1ko5E8OcnHfsOt9WmVq5joAnVZG9wj344BK2RpnkfJp9MzilWj8HTVl9C4TTaQqUwMyMbO3mh8eGWXRQruKqyAZ8YU2c39zRl3f04goxmFZYoi1VpCL3qrkyPx_ztUX1mrrudRXjtMdWvU_v3_le4BuefRaTjszOkhuWVnj8jdA3_-_pj8PARcSV0CTjjuGFnb3z9-hZ-7hL1JS-c1PV7lrocdU9IyxM3ecFTD8qZtYxbTetGGB0sDocRRRcM_jhdTGELRLOFV7sToYzgMd3GO6JFLFsNhHS2ac7t8Qr7u7x3vfqG-jAM1KZNzWlpmIpblJfg6i2MNALVksc5MlGXMCgmATALsgXCXxjyR3GhdcZFomBHNq6qIn5LBrJ7Z5yQEdJPo3Og0KZmwPAflSl1lzGibVHFSBYSv1KeM5zjHUhtTtWZndipXoHLlVK4uAvJ-_cxpx_BxY-8dtIp1T2Tndj_UzTflnV1FZZFHLC2MSROkWZW5jUrJU10BADNCBuQd2pTCGALDM4W_CgFCIhuXGkpETnEepwHZ6vUE3zf95pU5KR97WnVpSwF5s27GJzGfbmZBx9AnQyZAAKMBedYZ8VokgLAyEZwHRPbMuydzv2U2-e6YyfE-WgofBAH5sPKEy3H9e1Jf3CzGS7IZOR_FtMstMpg3C_uK3DHn80nbvPYu_wcWCVzC priority: 102 providerName: ProQuest |
| Title | Real-World Patients’ Diagnosis-to-Treatment Journey with Nontuberculous Mycobacterial Pulmonary Disease: A Cross-Sectional Survey |
| URI | https://link.springer.com/article/10.1007/s40121-024-01015-z https://www.ncbi.nlm.nih.gov/pubmed/38985411 https://www.proquest.com/docview/3083769925 https://www.proquest.com/docview/3077995397 https://pubmed.ncbi.nlm.nih.gov/PMC11266326 https://doaj.org/article/2da9206acc65482789e2d816bf081c48 |
| Volume | 13 |
| WOSCitedRecordID | wos001270032100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2193-6382 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001284197 issn: 2193-8229 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAVX databaseName: SpringerOpen customDbUrl: eissn: 2193-6382 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001284197 issn: 2193-8229 databaseCode: C24 dateStart: 20121201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RFiEu5VkIlFWQkDiAJTtPh9t2aQWHXUXbgpaTFTsOrLTaRclupe2pEr-Cv8cvYew8IOUhwcWHeJL4MR5_tmc-AzxDjK6zIFAEsRAuULg2dlAzknm6kDQomKKZvWwinkz4bJakTVBY1Xq7t0eS1lJ3wW6BoR8jOKcQw4sWkosd2AsZT4xej5oYh3pnhQfM3qqCo9EnhtG8iZb5_Wd6M5Il7v_VPP80P131nbxygGrnpZNb_1ej27Df4FB3WCvOHbiml3fhxrg5ab8HX6aIIIl1tXHTmnu1-nb51X1du-bNK7JekbPWS92tOZG2rtnWdScrnMikLtVmsdpU7nir0GhYUmj8Y7pZoOZn5RY_Zc-GXrlDd2RahpxatzBTrNNNea639-HdyfHZ6A1pLmwgKqJ8TXJNlUfjJMdRTX1fIhTNqS9j5cUx1QFH6MUR4KBhi3wWcqakLFgQSlwkS1YUmX8Au8vVUj8EF3FMKBMlozCngWYJdimXRUyV1GHhh4UDrO00oRo2c3OpxkJ0PMy2dQW2rrCtKy4ceNG987nm8vir9JHRhU7S8HDbB6vyo2iGtfDyLPFolCkVhYZQlSfayzmLZIFQSwXcgedGk4SxFlg8lTVBD1hJw7slhtxgJD_xIwcOe5I4ylU_u9VF0ViZSviIn-MoSbzQgaddtnnTeM4tNfYxysSG8w9hpwMPatXtqoRglYcBYw7wnlL36tzPWc4_WQ5yE3kWIfR34GWr2z_K9edGffRv4o_hpmeHh3G4PITddbnRT-C6Ol_Pq3IAO_H0vUlnsU05pnzEBrB3dDxJpwNrFgZ2lwWfpW_H6Yfvr7ZZKA |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qBQEb3o9AgSCBWIBFnKeDhNDQUrVqZzRqp6i7EDsOjDSalGSmaLpC4iv4CT6KL-FeJ5l2iuiuC7axk_hxH8f29bkAzxCj69T3FUMshAsUockOas5SV-fS8XOunNQkm4h6PbG_H_eX4Fd7F4bCKlubaAx1VijaI3_tIVaIwjh2g3cHXxlljaLT1TaFRi0WW3r2DZds1dvNNZzf5667_mGwusGarAJMhY6YsEw7ynWiOEPRczxPIl7KHE9Gyo0iR_sC8YFAL4zaF3o8EFxJmXM_kPh7yfM89fC7F-Ai2nFOIWTRzscTezrC5yafC9oBjxGXenNPx9zW84k_jaFTZETsFrCjBV9oUgb87RhOeMbTUZunjm6NR1y__r-N5Q241mBvu1Mry01Y0uNbcLnbRBfchh87iJqZCS-y-zXfbPX7-097rQ5HHFZsUrBBG5lv1zxQM5u2su1egc5b6lJNR8W0srszhYbSEGHjH_vTEXY5LWf4KXMe9sbu2Ks0J2zXhMJRs3an5aGe3YG9cxmCu7A8Lsb6PtiI3QIZKxkGmeNrHqMwCZlHjpI6yL0gt4C34pKohsGdEomMkjn3tBGxBEUsMSKWHFnwcv7OQc1fcmbt9ySF85rEPW4eFOXnpDFliZulseuEqVJhQCSyItZuJngoc4SXyhcWvCAZTshCYvNU2lz0wE4S11jSEYQLvdgLLVhZqImWTS0Wt-KbNJa1So5l14Kn82J6k6IFxxrnGOtExHOIUNuCe7XSzLuEAF0EPucWiAV1WujzYsl4-MXwrtNtuxCXOxa8ajXvuF3_HtQHZ3fjCVzZGHS3k-3N3tZDuOoa-0ABpiuwPCmn-hFcUoeTYVU-NsbGhk_nrZF_AAPptKE |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VgiouvB-GAkYCcYBVvX6ukRAKCRVVaRTRIvVmvOs1RIriYidF6QmJX8Ff4efwS5hZ22ldRG89cI3Xzj6-eezuzDcAT9BH16nvK4a-EG5QhCY9qDlLXZ1Lx8-5clJTbCIaDsX-fjxagV9tLgyFVbY60SjqrFB0Rr7hoa8QhXHsBht5ExYxGmy-PvjKqIIU3bS25TRqiGzrxTfcvlWvtga41k9dd_PtXv8dayoMMBU6YsYy7SjXieIMYeh4nkTfKXM8GSk3ihztC_QVBFpklMTQ44HgSsqc-4HErkie56mH370AFyMPUUxZ6n1-4nxH-NzUdkGd4DHiVW9ydkzmnk9cagwNJCOSt4AddeyiKR_wt5E4YSVPR3CeusY11nHz6v88r9fgSuOT271aiK7Dip7egLWdJurgJvz4gN40M2FH9qjmoa1-f_9pD-owxXHFZgXbayP27ZofamHTEbc9LNCoS12q-aSYV_bOQqECNQTZ-I-j-QSHnJYL_JS5J3tp9-w-rQ_bNSFy1K3deXmoF7fg47lMwW1YnRZTfRds9OkCGSsZBpnjax4jsITMI0dJHeRekFvAW-gkqmF2pwIjk2TJSW3gliDcEgO35MiC58t3DmpekzNbvyFELlsSJ7n5oSg_J42KS9wsjV0nTJUKAyKXFbF2M8FDmaPbqXxhwTPCc0KaE7un0iYBBAdJHGRJT5C_6MVeaMF6pyVqPNV93EI5aTRulRzj2ILHy8f0JkURTjWuMbaJiP8QXXAL7tQCtBwSOu4i8Dm3QHREqzPm7pPp-IvhY6csvBC3QRa8aKXwuF__ntR7Zw_jEayhICbvt4bb9-Gya1QFxZ2uw-qsnOsHcEkdzsZV-dDoHRs-nbdA_gGMt7z8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-World+Patients%E2%80%99+Diagnosis-to-Treatment+Journey+with+Nontuberculous+Mycobacterial+Pulmonary+Disease%3A+A+Cross-Sectional+Survey&rft.jtitle=Infectious+diseases+and+therapy&rft.au=Morimoto%2C+Kozo&rft.au=Gallagher%2C+Jack+R.&rft.au=Wagner%2C+Dirk&rft.au=Griffith%2C+David+E.&rft.date=2024-08-01&rft.issn=2193-8229&rft.eissn=2193-6382&rft.volume=13&rft.issue=8&rft.spage=1907&rft.epage=1920&rft_id=info:doi/10.1007%2Fs40121-024-01015-z&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s40121_024_01015_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2193-8229&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2193-8229&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2193-8229&client=summon |